M. Fabbro

UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer.

J. Lemonnier, J. Pierga, P. Viens, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial)

T. Delozier, V. Bardou, P. Viens, 1999, British Journal of Cancer.

High-dose sequential chemotherapy with recombinant granulocyte colony-stimulating factor and repeated stem-cell support for inflammatory breast cancer patients: does impact on quality of life jeopardize feasibility and acceptability of treatment?

T. Delozier, P. Viens, J. Moatti, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

C. Tournigand, M. Espié, B. Weber, 2019, The Lancet.

A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer.

P. Viens, A. Floquet, A. Gonçalves, 2008, Gynecologic oncology.

Phase III randomized trial of high-dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) support as consolidation in patients (pts) with advanced ovarian cancer (AOC): 5-year follow-up of a GINECO/FNCLCC/SFGM-TC study.

E. Pujade-Lauraine, M. Fabbro, H. Curé, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.